Iterum Therapeutics plc (ITRMF): Nasdaq/NYSE listing notice — Iterum Therapeutics receives Nasdaq delisting notice for bid price below $1.00

Iterum Therapeutics plc

Nasdaq notice for non-compliance with minimum bid price rule; shares traded below $1.00 for 30 consecutive business days.
180-day cure period expires February 23, 2026; must close at $1.00 for 10 consecutive business days to regain compliance.
May qualify for an additional 180-day period if it meets other listing standards and intends to cure via reverse split.
Failure to cure could lead to delisting; company will monitor options but no assurance of regaining compliance.

item 3.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

Iterum Therapeutics plc received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: minimum bid price
Rules: 5550(a)(2)

Exact text from the filing

August 25, 2025, Iterum Therapeutics plc (the “Company”) received a letter (the “Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market, LLC (“Nasdaq”) indicating that, based on the closing bid price for the last 30 consecutive business days, the Company is not in compliance with Nasdaq Listing Rule 5550(a)(2), which requires the Company maintain a minimum bid price of $1.00 per share (the “Bid Price Rule”) for continued listing on The Nasdaq Capital Market. The Notice does not result in the immediate delisting of the Company’s ordinary shares from The Nasdaq Capital Ma

View on SEC.gov

8 listing & compliance notices filed in the last 30 days. Browse all listing & compliance notices →

Iterum Therapeutics plc filing history →

Source: SEC EDGAR

accession 0000950170-25-111974

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.